On the other hand, PCSK9 inhibition early after the ACS event is mentioned in a 2022 European Clinical Consensus [64], in which it is stated that patients with increased ischemic risk factors (multivessel disease, familial hypercholesterolemia) that are unlikely to achieve LDL-C targets or patients required to achieve LDL-C levels < 40 mg/dL (recurrent ischemic events in less than 2 years) may benefit from the addition of PCSK9 inhibitor early on. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.